The University of British Columbia
UBC - A Place of Mind
The University of British Columbia
Faculty of MedicineAntineoplastic Drug Exposure Monitoring Program | School of Population & Public Health
  • Home
  • About
    • Health Hazards
    • Regulations & Guidelines
    • Organization & Funding
    • Contact
  • Lab Services
    • Methods
    • Equipment
  • Research
    • Alberta & Minnesota Cancer Centers
    • BC Veterinarians Antineoplastics Use Survey
    • BC Cancer Centres
  • Publications
    • Seminars
    • Conference Presentations
    • Published Papers
    • Upcoming Papers
    • Previous Work by Authors
  • People
  • The Antineoplastic Drug Exposure Monitoring Program

    Researchers at UBC’s School of Population and Public Health are working to characterize where and how antineoplastic drug contamination occurs in pharmacy and clinical settings as well as veterinary and research facilities.

  • Antineoplastic Drug Detection

    We offer a novel wipe sampling and high-performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) analysis method for the simultaneous detection of 11 antineoplastic drugs.

  • Improved Decontamination Procedure

    The Antineopastic Drug Exposure Monitoring Program aims to improve antineoplastic drug decontamination and guide surveillance methods and policies to better protect healthcare workers.

The Antineoplastic Drug Exposure Monitoring Program is part of the Department of Occupational and Environmental Health at the UBC School of Population and Public Health in Vancouver, Canada.

Antineoplastic drugs are used in treatment of cancer and other diseases in humans, and increasingly in companion pets. These drugs have huge benefits for to those suffering from disease. However, to healthcare workers (and to veterinary staff) who must handle the drugs every day, potentially for a lifetime, they present many occupational health hazard. Studies of exposures in healthcare workers have shown increasing rates of adverse reproductive effects, and cancer. Previous studies have documented antineoplastic drug residues on surfaces in pharmacy, nursing and patient-care areas.

There are no regulated exposure limits in Canada, or elsewhere. Variability of contaminants across surfaces is poorly understood making it difficult to develop sampling guidance. Nevertheless, monitoring contamination using surface wipe testing is now required by safe drug handling guidelines, such <USP 800>. Regular screening for contamination by AD will help to identify contamination levels, sources, pathways and determinants of exposure, with the ultimate goal to prevent of worker exposure.

Currently, we have the capacity to simultaneously detect the following 11 antineoplastic drugs from surface wipe sampling in order to better characterize where and how contamination occurs in healthcare, veterinary, and research facilities:

5-Fluorouracil

Bortezomib

Cyclophosphamide

Docetaxel

Gemcitabine

Ifosfamide

Methotrexate

Oxaliplatin

Paclitaxel Vinblastine Vincristine

 

 

 

 

 

Drug information courtesy of the BC Cancer Drug Manual [Abiraterone. Revised 1 August 2017. In: BC Cancer Drug Manual®. Badry, Nadine (editor). BC Cancer. Vancouver, British Columbia. Available at http://www.bccancer.bc.ca/. (Accessed 14 February 2019).]

Upcoming Events


There are no upcoming events at this time. Please check back later.

Antineoplastic Drug Exposure Monitoring Program | School of Population & Public Health
Faculty of Medicine
360A - 2206 East Mall
Vancouver, BC Canada V6T 1Z3
Tel 604 822 6777
Email hugh.davies@ubc.ca
Back to top
The University of British Columbia
  • Emergency Procedures |
  • Terms of Use |
  • Copyright |
  • Accessibility